American Healthcare REIT Inc
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
Compensation Discussion and Analysis
Introduction
This Compensation Discussion and Analysis outlines the principles underlying our executive compensation policies and decisions as it relates to our named executive officers, or NEOs. Our NEOs and their positions held for the year ended December 31, 2023 were:
Danny Prosky — Chief Executive Officer and President
Brian S. Peay — Chief Financial Officer
Gabriel M. Willhite — Chief Operating Officer
Stefan K.L. Oh — Chief Investment Officer
Mark E. Foster — Executive Vice President, General Counsel and Secretary
The Compensation Committee believes that our compensation program for executive officers is an important tool to:
attract, retain and motivate highly-skilled executives;
encourage management to balance short-term goals and longer-term objectives without incentivizing excessive risk-taking;
achieve an appropriate balance between risk and reward that does not incentivize excessive risk-taking; and
align the interests of management and stockholders through the use of equity-based compensation.
The Compensation Committee applied this philosophy in establishing each of the elements of executive compensation for the fiscal year ended December 31, 2023.
Our Compensation and Governance Practices & Policies
We believe the following practices and policies promote sound compensation governance and are in the best interests of our stockholders and executives:
| What We Do | What We Don’t Do |
|---|---|
| ✓ Compensation Committee comprised solely of independent directors | x No significant perquisites |
| ✓ Independent compensation consultant | x No minimum guaranteed base salary increases |
| ✓ Significant portion of total compensation in the form of equity awards with long-term vesting | x No tax gross ups to our NEOs |
| ✓ Significant portion of total compensation is based on performance and is not guaranteed | x We have a defined program that does not allow for uncapped bonus payouts |
| ✓ We enhance executive officer retention with time-based, multi-year vesting equity incentive awards | x We do not allow hedging or pledging of our securities |
| ✓ We use multiple performance measures for cash bonuses and multi-year equity awards, which mitigates compensation-related risk | x We do not provide single-trigger change in control cash severance payments |
Determining Compensation for Named Executive Officers
Role of Compensation Committee
The Compensation Committee is comprised entirely of independent directors and operates under a written charter. The Compensation Committee is responsible for determining compensation for all of our NEOs including evaluating compensation policies, approving target and actual compensation for executives and administering our equity incentive programs.
Role of Management
Our Chief Executive Officer plays an important role in setting compensation for our other executive officers by assisting the Compensation Committee in evaluating individual goals and objectives and developing compensation recommendations for NEOs other than himself. Final decisions on the design of the compensation program, including total compensation, are ultimately made by the Compensation Committee.
Role of Compensation Consultant
The Compensation Committee is authorized to retain the services of a compensation consultant to be used to assist in the review and establishment of our compensation programs and related policies. For 2023 compensation, at the recommendation of management, the Compensation Committee retained Ferguson Partners Consulting, L.P., or FPC, as its independent compensation consultant to advise it on executive officer and director compensation. FPC did not provide any other services to management. The Compensation Committee believes that there are no conflicts of interest with respect to FPC’s services.
Results of 2023 Advisory Vote on Executive Compensation
At our 2023 annual meeting of stockholders, we asked our stockholders to approve, on an advisory (non-binding) basis, the compensation paid to our NEOs for the year ended December 31, 2022. Our stockholders showed support for our executive compensation program, with 86.0% of the votes cast approving the advisory resolution. The Compensation Committee did not make any changes to our executive compensation program in response to the 2023 advisory vote on executive compensation.
Benchmarking and Peer Group Comparisons
The Compensation Committee reviews competitive compensation data from a select group of peer companies and broader survey sources. Although comparisons of compensation paid to our NEOs relative to compensation paid to similarly situated executives in the survey and by our peers assist the Compensation Committee in determining compensation, the Compensation Committee principally evaluates executive compensation based on corporate objectives and individual performance. Additionally, as part of its engagement, FPC provided the Compensation Committee with comparative market data on the overall compensation program for our executive officers based on an analysis of peer companies. In developing our peer group, the Compensation Committee took into consideration the following characteristics:
Portfolio size;
Market capitalization and total capitalization;
Asset class of portfolio; and
Pre-listing history (emergence from non-listed REIT market to listed REIT market).
The table set forth below identifies the companies in the peer group used for 2023, which the Compensation Committee considered as part of its analysis in setting compensation for our executive officers. This was the same peer group that was established and used in connection with compensation decisions made at the time of the AHI Acquisition.
| 2023 Executive Compensation Peer Group | ||
|---|---|---|
| Brandywine Realty Trust | Highwood Properties, Inc. | Piedmont Office Realty Trust, Inc. |
| CareTrust REIT, Inc. | LTC Properties, Inc. | Retail Opportunity Investments Corp. |
| Global Medical REIT Inc. | National Health Investors, Inc. | Sabra Health Care REIT, Inc. |
| Peakstone Realty Trust | Orion Office REIT, Inc. | Sila Realty Trust, Inc. |
| Healthcare Realty Trust Incorporated | Physicians Realty Trust | SmartStop Self Storage REIT, Inc. |
Alignment of Pay and Performance
We maintain a target compensation program that is designed to appropriately align the compensation of our executives with performance. For 2023, approximately 78.6% of our Chief Executive Officer’s target pay was performance-based/at risk and approximately 70.2% of target pay for the remaining NEOs was performance-based/at risk. The pay mix of our executives for 2023 is shown below:
Elements of Compensation
For 2023, our executive compensation program for our NEOs consisted of base salary, a short-term incentive cash bonus and long-term equity incentive awards. The material components of our 2023 executive compensation program are summarized in the following chart:
| Base Salary | Fixed level of competitive base pay to attract and retain executive talent generally based on scope and complexity of role and responsibilities |
|---|---|
| Short-Term Incentive Program | Designed to reward our NEOs for the achievement of annual corporate performance goals and individual performance goals•Includes 70% (varies by executive officer) of objectively evaluated metrics for corporate performance•Includes 30% (varies by executive officer) of subjectively evaluated strategic goals and individual performance |
| Long-Term Incentive Program | Awarded to encourage retention and alignment with the long-term growth and performance that maximizes stockholder value. 25% of total award is performance-based, and 75% is time-based and subject to the NEO’s continued employment or provision of services |
Base Salary
We provide base salaries to our NEOs to compensate them for services rendered on a day-to-day basis. Base salary is also intended to attract and retain executive officers and is generally based on the scope and complexity of the role and responsibilities, experience, individual performance and contributions, and internal pay equity considerations, taking into account comparable company data provided by our compensation consultant and based upon the Compensation Committee’s understanding of compensation paid to similarly situated executives, adjusted as necessary to recruit or retain specific individuals. The Compensation Committee seeks to target our NEOs’ base salaries at competitive levels to recognize professional growth, success and/or increased responsibilities. We believe that providing a competitive base salary relative to the companies with which we compete for executive talent is a necessary element of a compensation program that is designed to attract and retain talented and experienced executives. We also believe that attractive base salaries can motivate and reward our executive officers for their overall performance. Base salaries are reviewed annually by the Compensation Committee to assess if adjustments are necessary.
The base salaries for our NEOs for 2023 and 2022 are shown below.
| Named Executive Officer · 2023 Salary · 2022 Salary · % Change | ||||
|---|---|---|---|---|
| Danny Prosky | $750,000 | $750,000 | — | |
| Brian S. Peay | $475,000 | $475,000 | — | |
| Gabriel M. Willhite | $425,000 | $425,000 | (1) | — |
| Stefan K.L. Oh | $400,000 | $400,000 | — | |
| Mark E. Foster | $360,000 | $360,000 | — | |
(1) Reflects Mr. Willhite’s annualized base salary following his promotion in August 2022.
Short-Term Incentive Program (Cash Bonuses)
As part of our compensation program, our NEOs are entitled to receive an annual cash bonus within a specified range based on a percentage of their base salary. The following table sets forth the threshold (as a percentage of target), target (as a percentage of base salary), and maximum (as a percentage of target) bonus opportunities for each NEO under our annual cash bonus program and used in determining 2023 awards:
| Named Executive Officer | Threshold | Target | Maximum |
|---|---|---|---|
| Danny Prosky | 50% | 100% | 150% |
| Brian S. Peay | 50% | 100% | 150% |
| Gabriel M. Willhite | 50% | 100% | 150% |
| Stefan K.L. Oh | 50% | 75% | 150% |
| Mark E. Foster | 50% | 65% | 150% |
In determining the size of cash bonus awards, the Compensation Committee, in consultation with FPC, thoroughly reviews our corporate performance and the individual performance of the NEOs. For 2023, individual performance was evaluated subjectively by the Compensation Committee while corporate performance was evaluated objectively, with corporate performance being evaluated against pre-determined performance metrics and hurdles. For 2023, the objective performance metrics included Adjusted EBITDA Growth (excluding grant income), our net debt to adjusted EBITDA and our same-property NOI Growth (as defined below, and excluding grant income), as described further below. Our 2023 performance measures were selected based on a careful assessment of measures that we believe encourage profitable growth and increase shareholder value, while also motivating executives to perform at their highest levels despite interest rate volatility impacting the real estate markets. For 2023, corporate performance was weighted at 70%, and individual performance was weighted 30% for all of our NEOs.
The following table sets forth the performance metrics and goals approved by the Compensation Committee to determine corporate performance:
| Metric · Weighting · Performance Hurdles · Actual 2023Performance · Target Met | ||||||
|---|---|---|---|---|---|---|
| Threshold(50% Payout) · Target(100% Payout) · Maximum(150% Payout) | ||||||
| Adjusted EBITDA Growth | 40% | 7.50% | 8.50% | 9.00% | 14.20% | Maximum |
| Net Debt to Adjusted EBITDA | 30% | 9.1x | 8.85x | 8.6x | 8.8x | Target |
| Same-Property NOI Growth | 30% | 3.00% | 4.00% | 5.00% | 9.20% | Maximum |
| 2023 Performance Metrics | |
|---|---|
| Adjusted EBITDA Growth | •EBITDA is a non-GAAP financial measure that is defined as earnings before interest, taxes, depreciation and amortization.•Adjusted EBITDA is defined as EBITDA excluding the impact of stock-based compensation expense, acquisition and pursuit costs, gain (loss) on sales of real estate, unrealized foreign currency gain (loss), change in fair value of financial instruments, impairment of real estate assets, lease termination revenue, non-recurring items and adjusted for non-controlling interest.•Adjusted EBITDA Growth is calculated as the percentage increase/(decrease) of current year Adjusted EBITDA less grant income over prior year’s Adjusted EBITDA less grant income.•We use Adjusted EBITDA Growth to measure and assess our earnings growth on an unleveraged basis. Moreover, it is an important and closely followed measure of our performance by the investing community and our stockholders. |
| Net Debt to Adjusted EBITDA | •Net Debt is our consolidated short-term and long-term debt less our consolidated total and cash and cash equivalents.•Adjusted EBITDA is defined as EBITDA excluding the impact of stock-based compensation expense, acquisition and pursuit costs, gain (loss) on sales of real estate, unrealized foreign currency gain (loss), change in fair value of financial instruments, impairment of real estate assets, lease termination revenue, non-recurring items, and adjusted for non-controlling interest.•We believe Net Debt to Adjusted EBITDA indicates the strength of our company’s balance sheet and reflects our ability to generate sufficient earnings to service our indebtedness over time. |
| Same-Property NOI Growth | •NOI is defined as net income (loss), computed in accordance with GAAP, generated from properties before general and administrative expenses, business acquisition expenses, depreciation and amortization, interest expense, gain or loss on dispositions, impairment of real estate investments, impairment of intangible assets and goodwill, income or loss from unconsolidated entities, gain on re-measurement of previously held equity interest, foreign currency gain or loss, other income, and income tax benefit or expense.•Same-Property NOI is NOI from assets held by us for one year or more.•Same-Property NOI Growth is calculated as the percentage increase/(decrease) of current year Same-Property NOI less grant income over prior year’s Same-Property NOI less grant income.•We consider Same-Property NOI Growth to be indicative of the organic growth embedded in our property portfolio, which ordinarily can be an important driver of property values. It also is a metric typically evaluated by investors and analysts and is used by many of our peers to evaluate operating performance. |
To determine individual performance, our Compensation Committee took into consideration the following 2023 key accomplishments by our Named Executive Officers:
| Named Executive Officer | Key Accomplishments |
|---|---|
| Danny Prosky | •Led our success in reaching or exceeding our targets for EBITDA growth, same-property NOI growth and leverage ratios.•Implemented plans to achieve our overall strategic goals, focusing on maximizing the value of our real estate portfolio and ensuring that each department within our company has the talent and resources necessary to succeed. |
| Named Executive Officer | Key Accomplishments |
|---|---|
| Danny Prosky — (Continued) | •Committed substantial time and effort mentoring, grooming and improving our investment and asset management teams and processes to strategically sell selective properties at attractive capitalization rates, improve the overall quality of the portfolio, increase same-property NOI and maintain high occupancy rates in the portfolio.•Served as a member of the Board of Directors of Trilogy, tasked with overseeing its continued recovery from the COVID-19 pandemic.•Developed and maintained key external relationships with peers, material tenants, operators and other significant parties in the healthcare real estate space.•Committed substantial time meeting with and developing relationships with potential institutional investors in order to enhance their exposure to our company in anticipation of raising institutional capital. |
| Brian S. Peay | •Implemented proactive measures to protect and enhance our company’s balance sheet, liquidity and financial flexibility to support its business objectives.•2024 Offering Preparation•Assisted in the preparation and review of multiple filings with the SEC of our Registration Statement on Form S-11 in preparation for the 2024 Offering.•Led our efforts in preparing financial information and meeting with investment banking advisors and analysts, critical to execution of the 2024 Offering, resulting in the largest REIT public offering in connection with an exchange listing since 2018 (1).•Participated in multiple rounds of testing-the-waters meetings, both in-person and virtually, with potential institutional investors.•Improved our quarterly supplemental reporting package to be publicly filed with the SEC to support analysts’ and investors’ understanding of our business model and earnings. •Recruited and hired a Vice President of Investor Relations and Capital Markets instrumental in our messaging to analyst and investor communities.•Performed portfolio review meetings with each of our outpatient medical and long-term care asset management teams to understand key trends in the business and potential effects on earnings and cash flow. |
| Gabriel M. Willhite | •2024 Offering Preparation•Contributed significantly to the preparation of our Registration Statement on Form S-11 filed with the SEC in connection with the 2024 Offering, resulting in the largest REIT public offering in connection with an exchange listing since 2018 (1).•Led our efforts in preparing roadshow and testing-the-waters marketing materials in connection with the 2024 Offering.•Met with investors providing background on our company and its growth prospects.•Significant meetings with research analysts providing education on our company. |
| Named Executive Officer | Key Accomplishments |
|---|---|
| Gabriel M. Willhite — (Continued) | •Trilogy•Was appointed to Chairman of the Board of Trilogy Investors, our single-largest investment.•Oversaw performance and investments made through Trilogy Investors which had 12.4% NOI growth in 2023.•Led negotiations securing a purchase option for the minority interest of Trilogy Investors owned by a joint venture partner in a highly flexible and complex structure that allows for flexibility around timing and consideration.•Information Technology•Oversaw the establishment of our cybersecurity committee and assumed the role of chairman of the committee.•Oversaw the implementation of advancements in our cybersecurity protocols, including the development of our Cybersecurity Incident Management Plan.•Human Resources•Led the reorganization of the human resources department that included identifying and hiring a new head of human resources and a new head of payroll.•Oversaw a significant improvement and advancements in human resources policies, including the first year of fully online performance reviews.•Investment committee•Served as a member of our investment committee that evaluates all significant company investments and dispositions. |
| Stefan K.L. Oh | •Assumed the position of Chief Investment Officer in March 2023.•Enhanced Portfolio Quality: Led our investment and asset management teams in a strategic effort to enhance the overall quality of the portfolio through selective disposition of properties, contributing to better same-property NOI performance and EBITDA growth.•Generated Sales Proceeds: Oversaw the sale of senior housing and medical outpatient buildings at attractive pricing, resulting in approximately $195 million in gross sales proceeds and enhancing our leverage metrics.•Risk Management and Performance Optimization: Collaborated with the asset management teams to manage risk and optimize portfolio performance. This included operator realignment, leasing initiatives, and strategies to mitigate potential downside risks, including the conversion of two senior housing leased portfolios to SHOP.•Investment Structuring: Actively participated in structuring and negotiating the purchase option for the minority-held investment interest of Trilogy.•Stakeholder Relationships: Established and nurtured essential external connections with peers, tenants, operators, capital markets professionals, and other important stakeholders within the healthcare real estate industry. |
| Mark E. Foster | •Actively managed and reduced outside counsel legal expenses through fixed-fee arrangements, implementation of standard fee reductions and negotiation of legal fees where appropriate.•Successfully reduced legal expenses by hiring a new corporate attorney to reduce the use of outside counsel on certain corporate, securities and transactional matters. |
| Named Executive Officer | Key Accomplishments |
|---|---|
| Mark E. Foster — (Continued) | •Oversaw updates to various corporate forms to mitigate potential exposure to risk, reduce unanticipated expenses, and align economic incentives at the asset level.•Provided legal support for human resource-related matters, including the transition of certain key personnel.•Conducted a review and assessment of corporate policies and procedures to identify necessary updates or new policy implementation in anticipation of the 2024 Offering. •Actively managed potential regulatory and compliance-related matters to minimize our risks.•Direct involvement with respect to SEC filings related to the 2024 Offering.•Worked closely with our business teams on strategic transactions, including: (i) an option to acquire the remaining interests in Trilogy; (ii) the disposition of non-strategic assets; (iii) appointment of a receiver with respect to assets in Oregon; (iv) various financing transactions; (v) tenant lease restructurings and operational transitions, and (vi) other strategic corporate transactions. •Oversaw and provided strategic input with respect to asset-based litigation and pending business disputes. |
(1) Nareit. (2024)Historical IPOs. Retrieved from www.reit.com/data-research/reit-market-data/reit-capital-offerings
Based on its assessment of our corporate performance and each NEO’s individual performance and respective weightings described above, the Compensation Committee approved cash bonuses for 2023 in the following amounts:
| 2023 Cash Bonus | ||
|---|---|---|
| Named Executive Officer | Payout | As a % of Target |
| Danny Prosky | $949,500 | 126.6% |
| Brian S. Peay | $601,350 | 126.6% |
| Gabriel M. Willhite | $538,050 | 126.6% |
| Stefan K.L. Oh | $379,800 | 126.6% |
| Mark E. Foster | $296,244 | 126.6% |
Long-Term Incentive Program (Equity-Based Compensation)
As part of our compensation program, our NEOs are entitled to receive equity-based compensation. To encourage retention and alignment with our long-term growth and performance, 25% of such equity-based awards are performance-based and the remaining 75% of such awards are time-based.
Our NEOs received the following equity awards in 2023:
| Equity Awards | |||
|---|---|---|---|
| Named Executive Officer | Time-Based RSUs (#) (1) | Performance-Based RSUs (#) (2) | Aggregate Grant DateValue ($) (3) |
| Danny Prosky | 47,771 | 15,923 | 1,999,991 |
| Brian S. Peay | 20,303 | 6,767 | 849,998 |
| Gabe M. Willhite | 20,303 | 6,767 | 849,998 |
| Stefan K.L. Oh | 9,554 | 3,185 | 400,005 |
| Mark E. Foster | 8,957 | 2,986 | 375,010 |
(1) The number of time-based RSUs granted to the NEOs was determined based on the value of the equity awards determined by the Compensation Committee, divided by our estimated net asset value per share of Class T common stock of $31.40 available as of April 2023, rounded to the nearest whole share. These time-based RSUs vest in one-third annual increments, subject to each NEO’s continued service through the applicable vesting date.
(2) The number of performance-based RSUs subject to the award was determined based on the value of the equity awards determined by the Compensation Committee, divided by our net asset value per share of our Class T common stock of $31.40 available as of April 2023, rounded to the nearest whole share.
(3) Reflects the value of the NEOs’ respective equity award determined by the Compensation Committee was based on market data, consultation with FPC, NEO responsibilities and historical compensation practices
The performance-based RSUs will cliff vest in the first quarter of 2026 (subject to continuous employment or provision of services through that vesting date), with the amount of RSUs then vesting to be based on our Normalized FFO per share ranking over the three-year period ending December 31, 2025 versus a company peer group comprised of: CareTrust REIT, Inc., Healthcare Realty Trust Incorporated, LTC Properties Inc., National Health Investors, Inc., Physicians Realty Trust, Sabra Health Care REIT, Inc. and Omega Healthcare Investors, Inc., which peer group may be modified at the sole direction of our board or the Compensation Committee prior to the end of the three-year performance period to reflect changed circumstances such as the merger out of existence or significant portfolio modifications of such companies. Each NEO will vest into 50% of the RSUs subject to this grant if we achieve a “threshold” level of Normalized FFO per share, which is Normalized FFO-per-share performance that is 2.5% less than the peer group’s Normalized FFO-per-share performance (with no RSUs vesting if our Normalized FFO-per-share performance is worse than this amount); 100% of the RSUs if we achieve “target” performance, which is Normalized FFO-per-share performance equal to the peer group’s Normalized FFO-per-share performance; and 200% of the RSUs if we achieve “maximum” performance, which is Normalized FFO-per-share performance that is 2.5% or greater than the peer group’s Normalized FFO-per-share performance. There will be linear interpolation between Normalized FFO-per-share performance levels.
The following chart illustrates the terms of the 2023 performance-based award to the NEOs:
| 25% ofLTIP · Performance-Based RestrictedStock Units · Normalized FFO per Share · Payout % | ||
|---|---|---|
| Threshold | 2.5% Less than Peer Group | 50% |
| Target | Equal to Peer Group | 100% |
| Maximum | 2.5% Greater than Peer Group | 200% |
In 2023, the performance measure used for the Long-Term Incentive Program was Normalized FFO compared to modified FFO attributable to controlling interest, or Modified FFO, in 2022 to adopt a performance measure more closely aligned with that of our publicly listed REIT peers.
See Part III, Item 11, Executive Compensation — Executive Compensation Tables — 2023 Option Exercises and Stock Vested, for more information.
Risk Mitigation
Our executive compensation program is designed to achieve an appropriate balance between risk and reward that does not incentivize excessive risk-taking. Our Compensation Committee, in conjunction with FPC, conducts an annual risk assessment of our executive compensation program. As noted above, the Compensation Committee oversees, among other things, the assessment and management of risks related to our incentive compensation plans and equity-based incentive plan generally and whether our incentive compensation arrangements encourage excessive risk taking. We believe that our annual cash bonus program and equity compensation program contain appropriate risk mitigation factors, as summarized below:
balance of short-term and long-term incentives through annual cash bonuses and long-term equity compensation;
a substantial portion of total compensation is in the form of long-term equity awards;
a substantial portion of total compensation is based on achievement of performance objectives, through a combination of annual or multi-year performance. Furthermore, we incorporate both absolute and relative metrics by which to assess our performance;
three-year vesting based on continued service as of the vesting date; and
prohibition against hedging or pledging transactions.
Other Plans, Perquisites and Personal Benefits
Each of our NEOs is eligible to participate in our Executive Severance and Change in Control Plan, or our severance plan, as described below, and all of our compensatory and benefit plans on the same basis as our other employees. We provide an employer 50.0% matching contribution under our 401(k) profit sharing plan up to 5.0% of a participating employee’s contribution, including our NEO’s, taxable compensation, up to the Internal Revenue Service limitations for matching contributions.
Tax and Accounting Considerations
We have not provided or agreed to provide any of our executive officers or directors with a gross-up or other reimbursement for tax amounts they might pay pursuant to Section 4999 or Section 409A of the Code. Sections 280G and 4999 of the Code provide that executive officers, directors who hold significant stockholder interests, and certain other service providers could be subject to significant additional taxes if they receive payments or benefits in connection with a change in control of us that exceed certain limits, and that we or our successor could lose a deduction on the amounts subject to the additional taxes. Section 409A also imposes additional significant taxes on the individual in the event that an employee, director or service provider receives “deferred compensation” that does not meet the requirements of Section 409A.
Hedging Practices
Our Insider Trading Policy prohibits our directors and executive officers from entering into hedging or monetization transactions or similar arrangements with respect to our securities.
Compensation Committee Interlocks and Insider Participation
The Compensation Committee is currently composed of the independent directors listed as signatories to the below Compensation Committee Report. During 2023:
none of our executive officers were a director of another entity where one of that entity’s executive officers served on the Compensation Committee;
no member of the Compensation Committee was formerly an officer or employee of us or any of our subsidiaries;
no member of the Compensation Committee entered into any transaction with us in which the amount involved exceeded $120,000;
none of our executive officers served on the compensation committee of any entity where one of that entity’s executive officers served on the Compensation Committee; and
none of our executive officers served on the compensation committee of another entity where one of that entity’s executive officers served as a director on our board.
Option/SAR Grants in Last Fiscal Year
No option grants were made to our officers or directors for the year ended December 31, 2023.
Compensation Committee Report
The Compensation Committee has reviewed and discussed with management the information required by Item 402(b) of Regulation S-K and contained in the Compensation Discussion and Analysis section of this Annual Report on Form 10-K, and, based on such review and discussions, recommended to our board that the Compensation Discussion and Analysis be included in this Annual Report on Form 10-K for the year ended December 31, 2023.
Submitted by the Compensation Committee
of the Board of Directors:
Dianne Hurley (Chairwoman)
Marvin R. O’Quinn
Valerie Richardson
The preceding “Compensation Committee Report” shall not be deemed soliciting material or to be filed with the SEC, nor shall any information in this report be incorporated by reference into any past or future filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that American Healthcare REIT specifically incorporates it by reference into such filing.
Executive Compensation Tables
2023 Summary Compensation Table
The following table sets forth a summary of all compensation earned, awarded or paid, as applicable, to our NEOs in the fiscal years ended December 31, 2023 and 2022 and to the extent required by SEC executive compensation disclosure rules, December 31, 2021.
| Name and Principal Location | Year | Salary ($) | Bonus ($) (1) | Stockawards ($) (2) | Non-EquityIncentive Plan Compensation ($) (1) | All other compensation ($) (3) | Total ($) |
|---|---|---|---|---|---|---|---|
| Danny Prosky | 2023 | 750,000 | 225,000 | 1,999,991 | 724,500 | 85,189 | 3,784,680 |
| Chief Executive Officer and President | 2022 | 750,000 | 225,000 | — | 787,500 | 61,855 | 1,824,355 |
| 2021 | 187,500 | — | 2,000,003 | 187,500 | 23,040 | 2,398,043 | |
| Brian S. Peay | 2023 | 475,000 | 142,500 | 849,998 | 458,850 | 58,601 | 1,984,949 |
| Chief Financial Officer | 2022 | 475,000 | 142,500 | — | 498,750 | 51,011 | 1,167,261 |
| 2021 | 118,750 | — | 1,387,555 | 118,750 | 24,423 | 1,649,478 | |
| Gabriel M. Willhite | 2023 | 425,000 | 127,500 | 849,998 | 410,550 | 52,409 | 1,865,457 |
| Chief Operating Officer(4) | 2022 | 384,000 | 127,500 | — | 446,250 | 35,366 | 993,116 |
| 2021 | 90,000 | — | 1,061,591 | 58,500 | 15,549 | 1,225,640 | |
| Stefan K.L. Oh | 2023 | 400,000 | 90,000 | 400,005 | 289,800 | 41,803 | 1,221,608 |
| Chief Investment Officer | 2022 | 400,000 | 130,000 | — | 195,000 | 39,487 | 764,487 |
| 2021 | 100,000 | — | 962,550 | 65,000 | 18,559 | 1,146,109 | |
| Mark E. Foster | 2023 | 360,000 | 70,200 | 375,010 | 226,044 | 17,265 | 1,048,519 |
| Executive Vice President, General Counsel and Secretary(5) | 2022 | 135,000 | 70,200 | 156,248 | 245,700 | 4,261 | 611,409 |
| 2021 | — | — | — | — | — | — |
(1) Represents amount paid under the short-term incentive program for the fiscal years ended December 31, 2023, 2022 and 2021, with the portion in the Bonus column reflecting the individual component of the 2023 short-term incentive program and the portion in the Non-Equity Incentive Compensation column representing the formulaic payout based on the achievement of pre-established performance goals. See Part III, Item 11, Executive Compensation — Compensation Discussion and Analysis — Elements of Compensation — Short-Term Incentive Program (Cash Bonuses) for more information.
(2) The time-based RSUs and performance-based RSUs were awarded and granted in April 2023 under our incentive plan. The performance-based RSUs are calculated assuming target achievement (the most probable outcome at the time of grant) of the underlying performance condition at the time of grant. Assuming maximum achievement of the underlying performance condition at the time of grant, the grant date fair value of the 2023 performance-based RSUs granted to the NEOs would be as follows: Mr. Prosky, $999,964; Mr. Peay, $424,968; Mr. Willhite, $424,968; Mr. Oh, $200,018; and Mr. Foster, $187,521. See Part III, Item 11, Executive Compensation — Compensation Discussion and Analysis — Elements of Compensation — Long-Term Incentive Program (Equity-Based Compensation) for additional information regarding these awards.
(3) Amounts in the “All other compensation” column consist of the following payments we paid to or on behalf of the NEOs:
| Name | 401(k) Contributions ($) | Distributions Paid on Awards ($) |
|---|---|---|
| Danny Prosky | 7,979 | 77,210 |
| Brian S. Peay | 7,975 | 50,626 |
| Gabriel M. Willhite | 8,013 | 44,396 |
| Stefan K.L. Oh | 8,033 | 33,770 |
| Mark E. Foster | 7,242 | 10,023 |
(4) Mr. Willhite transitioned from his position as Executive Vice President, General Counsel to Chief Operating Officer, effective August 1, 2022; therefore, the amount of Mr. Willhite’s 2022 salary is based on the two positions he held in 2022.
(5) Mr. Foster was appointed as our Executive Vice President, General Counsel effective August 1, 2022, therefore his 2022 salary is pro-rated and he did not receive any compensation in 2021.
2023 Grants of Plan-Based Awards
The following table summarizes all grants of plan-based awards made to our NEOs in 2023.
| Estimated Future Payouts Under Non-Equity Incentive Plan Awards (1) · Estimated Future Payouts Under Equity Incentive Plan Awards (2) · All other stock awards: Number of shares of stock or units (#)(3) · Grant date fair value of stock and option awards ($) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name · Grant Date · Threshold ($) · Target ($) · Maximum ($) · Threshold (#) · Target (#) · Maximum (#) | |||||||||
| Danny Prosky | 78,750 | 525,000 | 787,500 | ||||||
| 4/3/2023 | 47,771 | 1,500,009 | |||||||
| 4/3/2023 | 7,962 | 15,923 | 31,846 | 499,982 | |||||
| Brian S. Peay | 49,875 | 332,500 | 498,750 | ||||||
| 4/3/2023 | 20,303 | 637,514 | |||||||
| 4/3/2023 | 3,384 | 6,767 | 13,534 | 212,484 | |||||
| Gabriel M. Willhite | 44,625 | 297,500 | 446,250 | ||||||
| 4/3/2023 | 20,303 | 637,514 | |||||||
| 4/3/2023 | 3,384 | 6,767 | 13,534 | 212,484 | |||||
| Stefan K.L. Oh | 31,500 | 210,000 | 315,000 | ||||||
| 4/3/2023 | 9,554 | 299,996 | |||||||
| 4/3/2023 | 1,593 | 3,185 | 6,370 | 100,009 | |||||
| Mark E. Foster | 24,570 | 163,800 | 245,700 | ||||||
| 4/3/2023 | 8,957 | 281,250 | |||||||
| 4/3/2023 | 1,493 | 2,986 | 5,972 | 93,760 | |||||
(1) Represents bonus opportunities for 2023 corporate performance under the short-term incentive program as approved by the Compensation Committee on April 3, 2023. The actual amount awarded will based on the achievement of certain performance measures as described under Part III, Item 11, Executive Compensation — Compensation Discussion and Analysis — Elements of Compensation — Short-Term Incentive Program (Cash Bonuses). Excluded from these columns will be the discretionary portion of the 2023 bonus program, which are reflected in the “Bonus” column in the 2023 Summary Compensation Table.
(2) Represents performance-based RSUs that will cliff vest in the first quarter of 2026 (subject to continuous employment or provision of services through that vesting date), with the amount of RSUs then vesting to be based on our relative Normalized FFO per share ranking over the three-year period ending December 31, 2025 versus a company peer group. The grant date fair value was measured based on the achievement of Normalized FFO per share performance at the target level (the most probable outcome as of the grant date), multiplied by our estimated net asset value per share of Class T common stock in effect on the grant date of $31.40.
(3) Represents time-based RSUs determined based on the value of the equity awards determined by the Compensation Committee, divided by our estimated net asset value per share of Class T common stock of $31.40 available as of April 2023, rounded to the nearest whole share. These time-based RSUs will vest in equal annual installments, with the first one-third installment vesting on April 3, 2024, the second one-third installment vesting on April 3, 2025 and the final one-third installment vesting on April 3, 2026 (subject to continuous employment or provision of services through each vesting date).
Outstanding Equity Awards at Fiscal Year-End December 31, 2023
The following table presents information about our NEOs’ outstanding equity awards as of December 31, 2023. The market value of such outstanding equity awards is based on our estimated net asset value per share of Class T common stock available as of December 31, 2023 of $31.40.
| Stock awards | ||||
|---|---|---|---|---|
| Name | Number of shares or units of stock that have not vested (#) (1) | Market value of shares or units that have not vested ($) (1) | Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#) (2) | Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($) (2) |
| Danny Prosky | 61,330 | 1,925,762 | 29,481 | 925,703 |
| Brian S. Peay | 42,675 | 1,339,995 | 11,851 | 372,121 |
| Gabriel M. Willhite | 41,462 | 1,301,907 | 9,309 | 292,303 |
| Stefan K.L. Oh | 29,045 | 912,013 | 5,388 | 169,183 |
| Mark E. Foster | 11,060 | 347,284 | 4,037 | 126,762 |
(1) Represents (a) restricted shares of Class T common stock that will vest in equal annual installments, with the first one-third installment vested on October 1, 2022, the second one-third installment vested on October 1, 2023 and the final one-third installment vesting on October 1, 2024 (Mr. Prosky, 13,559 restricted shares, Mr. Peay, 5,084 restricted shares, Mr. Willhite, 2,542 restricted shares, and Mr. Oh, 2,203 restricted shares) (subject to continuous employment or provision of services through each vesting date), except in the case of Mr. Foster as described below, (b) in the case of Messrs. Peay, Oh and Willhite, retention grants of restricted shares of Class T common stock that will vest on October 4, 2024 (Mr. Peay, 17,288 restricted shares, Mr. Willhite, 18,617 restricted shares, and Mr. Oh, 17,288 restricted shares) (subject to continuous employment or provision of services through the vesting date), (c) in the case of Mr. Foster, restricted shares of Class T common stock that will vest in three equal annual installments, with the first one-third installment vested on January 1, 2023, the second one-third installment vested on January 1, 2024 and the final one-third installment vesting on January 1, 2025 (2,103 restricted shares) (subject to continuous employment or provision of services through each vesting date), and (d) time-based RSUs that will vest in equal installments, with the first one-third installment vested on April 3, 2023, the second one-third installment vesting on April 3, 2024 and the final one-third installment vesting on April 3, 2025 (Mr. Prosky, 47,771 RSUs, Mr. Peay, 20,303 RSUs, Mr. Willhite, 20,303 RSUs, Mr. Oh, 9,554 RSUs, and Mr. Foster, 8,957 RSUs) (subject to continuous employment or provision of services through each vesting date).
(2) Represents (a) performance-based RSUs that will cliff vest in the first quarter of 2025 (subject to continuous employment or provision of services through that vesting date), which RSUs are scheduled to vest based on our Modified FFO performance (Mr. Prosky, 13,558 RSUs, Mr. Peay, 5,084 RSUs, Mr. Willhite, 2,542 RSUs, Mr. Oh, 2,203 RSUs, and Mr. Foster, 1,051 RSUs), and (b) performance-based RSUs that will cliff vest in the first quarter of 2026 (subject to continuous employment or provision of services through that vesting date), which RSUs are scheduled to vest based on our Normalized FFO performance (Mr. Prosky, 15,923 RSUs, Mr. Peay, 6,767 RSUs, Mr. Willhite, 6,767 RSUs, Mr. Oh, 3,185 RSUs, and Mr. Foster, 2,986 RSUs). Because our Modified FFO and Normalized FFO performance for purposes of these awards is not calculable as of the date of this filing, we have assumed performance at the target performance level (100% payout level) for purposes of this table.
2023 Option Exercises and Stock Vested
The following table sets forth, for each of our NEOs, the number of shares of our common stock that vested in 2023 as well as the value of those shares upon vesting. The value realized upon vesting is based on the estimated net asset value per share of Class T common stock available at the time of vesting.
| Stock awards | ||
|---|---|---|
| Name | Number of shares acquired on vesting (#) | Value realized on vesting ($) |
| Danny Prosky | 13,557 | 425,690 |
| Brian S. Peay | 5,084 | 159,638 |
| Gabriel M. Willhite | 2,542 | 79,819 |
| Stefan K.L. Oh | 2,203 | 69,174 |
| Mark E. Foster | 1,051 | 39,055 |
Potential Payments Upon Termination or Change in Control
We adopted our severance plan for the purpose of providing severance and change-of-control protections to certain key employees, including our NEOs. As described below, our severance plan provides our NEOs with, among other things, base salary, bonus and certain other payments at, following and/or in connection with certain terminations of employment or a change in control involving us. As used below, the terms “Cause,” “Change in Control,” “Disability” and “Good Reason” shall have the respective meanings set forth in our severance plan.
Termination Without Cause or Resignation for Good Reason
Under our severance plan, in the event a participant is terminated without Cause or resigns for Good Reason, such participant will be entitled to receive the following, including any accrued obligations entitled to such participant:
a severance payment in an amount equal to: (1) 2.0 if the participant is our Chief Executive Officer, 1.5 if the participant is our Executive Chairman, Chief Operating Officer, Chief Financial Officer, Head of Acquisitions/Chief Investment Officer or General Counsel, or 1.0 if the participant holds another position; multiplied by (2) the sum of: (a) such participant’s base salary, plus (b) such participant’s average cash bonus for the three most recent years completed prior to the termination, payable in equal installments in accordance with our normal payroll practices, commencing 60 days following the termination date;
for a period of time ending on the earlier to occur of (1) the completion of the applicable severance period as provided in our severance plan, and (2) the date on which the participant becomes eligible to receive healthcare coverage from a subsequent employer, medical coverage through our group medical plans pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, at the same levels as would have applied if the participant’s employment had not been terminated or reimbursement of the cost of such medical coverage;
any retention equity grants granted to the participant that are unvested as of the termination date shall vest and, if applicable, become exercisable and any other unvested restricted stock or other equity awards issued to the participant under our incentive plan or otherwise by us that are outstanding on the termination date and that vest solely based on the passage of time, or, each, a Time-Based Award, shall vest and become exercisable, if applicable, as to the number of shares subject to such award that would have vested over the 12-month period following the termination date had the participant remained employed; and
any performance-based vesting award issued to the participant under our incentive plan or otherwise by us, or, each, a Performance-Based Award, that remains outstanding on the termination date shall remain outstanding and eligible to be earned following the completion of the performance period based on the actual achievement of applicable performance goals, and to the extent earned (if at all) shall vest on a pro rata basis based on the number of days the participant remained employed from the commencement of the performance period through the termination date.
Change in Control Followed by Termination Without Cause or Resignation for Good Reason
In the event a Change in Control occurs:
any Time-Based Award that is then outstanding shall vest and, if applicable, become exercisable immediately prior to the Change in Control subject to the participant’s continued employment until immediately prior to such Change in Control;
any Performance-Based Award that is then outstanding and that is not continued, converted, assumed or replaced with a substantially similar award by us or a successor entity in connection with the Change in Control (in each case, such award being considered assumed, or Assumed), shall vest and, if applicable, become exercisable immediately prior to the Change in Control based on actual achievement of the applicable performance goals through the date of the Change in Control, as determined in the sole discretion of the Compensation Committee prior to consummation of the Change in Control; and
if, during the period beginning on the date of the Change in Control and continuing through the twelve (12) month period following such Change in Control, a participant is terminated without Cause (other than by reason of the death or Disability of such participant) or a participant resigns for Good Reason, such participant shall be entitled to receive each of the following, including any accrued obligations entitled to such participant:
a Change in Control severance payment, in an amount equal to: (1) 2.5 if the participant is our Chief Executive Officer, or 2.0 if the participant is not our Chief Executive Officer; multiplied by (2) the sum of: (a) the participant’s base salary; plus (b) the participant’s average cash bonus for the three most recent years completed prior to the termination, which amount shall be paid to the participant in a lump sum within 60 days following the termination date;
continuing medical coverage or a corresponding payment as described under “—Termination Without Cause or Resignation for Good Reason”; and
any Performance-Based Award that was Assumed in connection with such Change in Control and that remains unvested on the termination date shall, to the extent such award remains subject to performance-based vesting as of the termination date, remain outstanding and eligible to be earned following the completion of the performance period based on the actual achievement of applicable performance goals, and to the extent earned (if at all) shall vest on a pro rata basis based on the number of days the participant remained employed from the commencement of the performance period through the termination date.
Termination Other Than Without Cause or Resignation Other Than for Good Reason
In the event that a participant is terminated for any reason other than as set forth above, such participant shall be entitled to receive from us the accrued obligations entitled to such participant and, if such termination is due to the participant’s death or Disability: (1) an amount equal to 0.5 multiplied by such participant’s base salary, which amount shall be paid to the participant (or, if applicable, the participant’s beneficiary or to such participant’s estate, if a participant fails to make a beneficiary designation), in equal installments in accordance with our normal payroll practices for a period of six months after the termination date starting within 60 days following the termination date; (2) the participant’s annual cash performance bonus for the year in which the termination date occurs, as determined by the Compensation Committee based on target performance for the performance period and pro-rated for the number of days from the performance period commencement to the termination date, payable at its normal time (but in no event later than March 15 of the year following the year in which the termination date occurs); (3) all unvested Time-Based Awards shall vest and become exercisable, if applicable, as to the number of shares subject to such award that would have vested (and become exercisable) over the 12-month period following the termination date had the participant remained employed; and (4) any Performance-Based Awards shall remain outstanding and eligible to be earned following the completion of the performance period based on the actual achievement of applicable performance goals and, to the extent earned (if at all), shall vest on a pro rata basis based on the number of days the participant remained employed from the commencement of the performance period through the termination date.
The following table presents the amount of compensation payable to each of our NEOs as if the triggering termination event described above and pursuant to our severance plan had occurred on December 31, 2023:
| Name | Benefit | Termination Without Cause orResignation for Good Reason ($) | Termination Without Cause or Resignation for Good Reason within 12 months following Change in Control ($) | Death or Disability ($) |
|---|---|---|---|---|
| Danny Prosky | Severance Payment | 3,308,000 | 4,135,000 | 1,324,500 |
| Medical Coverage (1) | 60,543 | 75,679 | 15,136 | |
| Accelerated Vesting of Time-Based Awards | 925,735 | 1,925,762 | 925,735 | |
| Accelerated Vesting of Performance-Based Awards | 925,703 | 925,703 | 925,703 | |
| Brian S. Peay | Severance Payment | 1,571,300 | 2,095,067 | 838,850 |
| Medical Coverage (1) | 45,408 | 60,543 | 15,136 | |
| Accelerated Vesting of Time-Based Awards | 914,933 | 1,339,995 | 914,933 | |
| Accelerated Vesting of Performance-Based Awards | 372,121 | 372,121 | 372,121 | |
| Gabriel M. Willhite | Severance Payment | 1,310,400 | 1,747,200 | 750,550 |
| Medical Coverage (1) | — | — | — | |
| Accelerated Vesting of Time-Based Awards | 876,876 | 1,301,907 | 876,876 | |
| Accelerated Vesting of Performance-Based Awards | 292,303 | 292,303 | 292,303 | |
| Stefan K.L. Oh | Severance Payment | 1,082,400 | 1,443,200 | 579,800 |
| Medical Coverage (1) | 45,408 | 60,543 | 15,136 | |
| Accelerated Vesting of Time-Based Awards | 711,964 | 912,013 | 711,964 | |
| Accelerated Vesting of Performance-Based Awards | 169,183 | 169,183 | 169,183 | |
| Mark E. Foster | Severance Payment | 999,108 | 1,332,144 | 476,244 |
| Medical Coverage (1) | 32,464 | 43,285 | 10,821 | |
| Accelerated Vesting of Time-Based Awards | 126,730 | 347,284 | 126,730 | |
| Accelerated Vesting of Performance-Based Awards | 126,762 | 126,762 | 126,762 |
(1) Represents the cost of medical insurance coverage for each NEO at the same annual level as in effect immediately preceding December 31, 2023 for a period of time equal to the applicable multiple set forth in our severance plan. Such amounts are paid in equal installments over an annual period equal to the respective severance multiple (i.e., 2.5 years, 2 years, 1.5 years or 1 year). A lesser amount may be due if the NEO becomes eligible to receive healthcare coverage from a subsequent employer.
Listing Equity Awards
Our board granted 625,926 shares of restricted common stock to our NEOs pursuant to our incentive plan upon completion of the 2024 Offering, or the Listing Equity Awards. The Listing Equity Awards vest ratably over four years and are subject to continuous service through the vesting dates.
CEO Pay Ratio
As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(u) of Regulation S-K, presented below is the ratio of annual total compensation of our Chief Executive Officer, or CEO, to the annual total compensation of our median employee (excluding our CEO). The ratio presented below is a reasonable estimate calculated in a manner consistent with Item 402(u) of Regulation S-K under the Securities Exchange Act of 1934.
To identify the “median employee” from our employee population, we determined the annual total compensation of each of our employees as of December 31, 2023 in accordance with the requirements of Item 402(c)(2)(x) of Regulation S-K. We annualized base wages of any permanent employees who were employed for less than the full year or on unpaid leave during 2023, and we did not otherwise annualize or make any cost-of-living or other adjustments to employee compensation. Our employee population, including all full- and part-time employees, as of December 31, 2023 consisted of approximately 108 individuals, all of whom were located in the United States.
For 2023, our last completed fiscal year, annual total compensation as determined under Item 402 of Regulation S-K for our CEO was $3,784,680, as disclosed on page 95. The 2023 annual total compensation as determined under Item 402 of Regulation S-K for our median employee was $122,976. Based on this information, the ratio of our CEO's annual total compensation to our median employee's annual total compensation for fiscal year 2023 is 30.8 to 1. The SEC's rules for calculating the required pay ratio permit companies to use reasonable estimates and assumptions in their methodologies, and companies have different employee populations and compensation practices. As a result, pay ratios reported by other companies may not be comparable to the pay ratio reported above.
Director Compensation
If a director is also one of our employees, we do not pay any additional compensation to that person for services rendered as a director. Our director compensation program is designed with the goals of attracting and retaining highly qualified individuals to serve as directors and to fairly compensate them for their time and efforts. In 2023, our board reviewed and approved the director compensation program adjustments described below after considering input from FPC (as defined below), the independent compensation consultant retained by the Compensation Committee to advise on executive officer and director compensation. For the year ended December 31, 2023, our independent directors received the following forms of compensation:
| Type of fee | 2023 Amount |
|---|---|
| Annual Cash Retainer | |
| •All non-employee directors | •$85,000 annually, paid quarterly |
| •Additional Audit Committee Chairperson fee | •$20,000 annually, paid quarterly |
| •Additional Audit Committee Member fee | •$5,000 annually, paid quarterly |
| •Additional Compensation Committee or Nominating and Corporate Governance Committee Chairperson fee | •$12,500 annually, paid quarterly |
| •Additional Non-Executive Chairman of the Board fee | •$100,000 annually, paid quarterly |
| Equity Compensation | |
| •In connection with the initial election or subsequent re-election each year, each non-employee director receives an amount of restricted Class T common stock pursuant to our incentive plan that fully vests one year from the date of grant, subject to their continued service as a non-employee director and prorated for their term of service | •Prior to June 15, 2023, $85,000 annually•Effective as of June 15, 2023, $95,000 annually |
| Other Compensation | •Reimbursement of out-of- pocket expenses incurred in connection with attendance at Board meetings or Board Committee meetings. Such reimbursement is paid monthly. Our independent directors do not receive other benefits from us. |
2023 Director Compensation
The following table sets forth certain information with respect to our director compensation for non-employee directors for the year ended December 31, 2023.
| Name | Fees Earned or Paid in Cash ($) (1) | Stock Awards($)(2) | All Other Compensation ($) (3) | Total ($) |
|---|---|---|---|---|
| Jeffrey T. Hanson (4) | 185,000 | 94,985 | 1,513 | 281,498 |
| Danny Prosky | — | — | — | — |
| Mathieu B. Streiff (4) | 85,000 | 94,985 | 1,513 | 181,498 |
| Scott A. Estes | 100,000 | 94,985 | 3,595 | 198,580 |
| Brian J. Flornes | 102,500 | 94,985 | 16,856 | 214,341 |
| Harold H. Greene (5) | 51,250 | 82,738 | 11,651 | 145,639 |
| Dianne Hurley | 106,250 | 94,985 | 18,026 | 219,261 |
| Marvin R. O’Quinn (6) | 82,875 | 131,327 | 2,246 | 216,448 |
| Valerie Richardson (6) | 82,875 | 131,327 | 2,246 | 216,448 |
| Gerald W. Robinson (5) | 42,500 | 82,738 | 9,761 | 134,999 |
| J. Grayson Sanders (5) | 42,500 | 82,738 | 9,812 | 135,050 |
| Wilbur H. Smith III | 85,000 | 94,985 | 19,148 | 199,133 |
(1) Amounts reported in this column represent the annual retainer received by each individual who served as a non-employee director during 2023.
(2) Amounts reported in this column represent (a) the grant date fair value of the awards granted to the non-employee directors other than Messrs. Greene, Robinson and Sanders during the year ended December 31, 2023, as determined in accordance with Financial Accounting Standards Board ASC, Topic 718, Compensation — Stock Compensation, or FASB ASC Topic 718, based on the estimated net asset value per share of $37.16 or $31.40, as applicable, for our Class T common stock as of the date of grant and (b) in the case of Messrs. Greene, Robinson and Sanders, the incremental fair value under FASB ASC Topic 718 associated with the modification of their outstanding equity awards in connection with their retirements to provide for accelerated vesting of the unvested portion of their outstanding equity awards. The following table shows the aggregate number of nonvested shares of our restricted Class T common stock held by each non-employee director as of December 31, 2023:
| Director | Nonvested Shares of Our Restricted Class T Stock (#) |
|---|---|
| Hanson | 3,025 |
| Prosky | — |
| Streiff | 3,025 |
| Estes | 3,025 |
| Flornes | 3,400 |
| Greene | — |
| Hurley | 3,400 |
| O’Quinn | 3,025 |
| Richardson | 3,025 |
| Robinson | — |
| Sanders | — |
| Smith | 3,400 |
(3) Amounts reported in this column reflect the dollar value of distributions paid in connection with the stock awards granted to our independent directors or non-employee directors.
(4) Messrs. Hanson, Prosky and Streiff are not independent directors.
(5) Messrs. Greene, Robinson and Sanders served as independent directors who retired effective June 14, 2023. As such, amounts presented reflect compensation earned through their date of retirement.
(6) Mr. O’Quinn and Ms. Richardson were appointed to our board effective January 10, 2023.
AHR Incentive Plan
For a discussion of our incentive plan, See Note 13, Equity — Equity Compensation Plans, to the Consolidated Financial Statements that are a part of this Annual Report on Form 10-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.